Skip to main content
. 2016 Oct 3;2:16025. doi: 10.1038/cddiscovery.2016.25

Figure 3.

Figure 3

A flow cytometric analysis concerning the expression of (a) different T-cell subsets and (b) myeloid derivative cells (activated DCs and MDICs) in the PBMCs of mNSCLC patients enrolled in the BEVA2007 trial who have received the mPE doublet alone (Inline graphic) or combined with bevacizumab (Inline graphic). Results are expressed as fold induction relative to baseline indicated as 1 (±S.E.). Asterisks represent statistical significance to the correspondent baseline values (*P<0.05; **P<0.01).